Ranbaxy Signs Licensing & Supply Agreement to Market a Second Licensed Generic in Canada

Ranbaxy Laboratories Ltd on October 06, 2006 has announced that the Company's wholly owned subsidiary, Ranbaxy Pharmaceuticals Canada Inc. (RPCI) and Janssen-Ortho Inc. (JOI), have entered into a licensing and supply agreement for a generic fentanyl patch, sold under Ranbaxy's label, RAN^TM Fentanyl Transdermal System. This is the second product to be commercialized by RPCI as part of a licensing arrangement between the companies.

Ran^TM Fentanyl Transdermal System is classified as an opioid analgesic drug indicated for the management of persistent, moderate to severe chronic pain and is supplied in a patch form. The potential market for a generic fentanyl patch is expected to reach CAD 50 Million. RAN^TM Fentanyl Transdermal System will be available through pharmacies and wholesalers immediately.

Speaking on the licensing arrangement, Bill Abboud, President and General Manager for RPCI, said, "This agreement, which also includes Risperidone, will provide Ranbaxy with an opportunity to commercialize products that continue to have a favorable impact on patient care, as well as on the Canadian healthcare system, and allow Ranbaxy to reinforce its presence in Canada."

RAN^TM Fentanyl Transdermal System is a trademark of the Company.

Source : Equity Bulls

Keywords